Table 2. Development of chronic kidney disease during follow-up.
Overall (n = 587) | Users of RAS inhibitor (n = 94) | Non-users of RAS inhibitor (n = 493) | P value | |
---|---|---|---|---|
CKD development, N (%) | 233 (39.7%) | 25 (26.6%) | 208 (42.2%) | 0.005 |
Median CKD-free survival time, days | 574 | 1079 | 520 | 0.011 |
Abbreviation: CKD, chronic kidney disease.